According to the Zhitong Finance App, Dongyangyang Pharmaceutical (06887.HK) announced that the Degumendong Double Insulin Injection developed independently by the Group was officially approved for marketing by the China National Drug Administration (NMPA), covering both types of refills and pre-filled injection pens.

According to the Zhitong Finance App, Dongyangyang Pharmaceutical (06887.HK) announced that the Degumendong Double Insulin Injection developed independently by the Group was officially approved for marketing by the China National Drug Administration (NMPA), covering both types of refills and pre-filled injection pens.